Oppenheimer stops Kursziel and outperforms-Rating for Tarsus trotz Investing.com Investigative Predictions Festival

Tarsus Pharmaceuticals (NASDAQ:TARS) was priced positive and received an Outperform rating above US$63.00. The company’s analyst released a preview of the agencies’ financial report for the 2024 quarter and focused on reading XDEMVY, Tarsus’ product for managing Demodex-Blepharitis.

Obwohl a light Überschätzung der Gesamtverschreibungszahlen durch IQVIA erwartet wird, un Muster, car in den letzten Quartalen beobachtet wurde, prognosis Oppenheimer ainen Absatz von etwa 40.020 Flaschen. This Zahl is only at the forefront of analysts and advisors of 41,000 Flaschen.

Analysts’ overall forecast was US$44.3 million, it was expected to reach US$44 million, and it beat other analysts’ consensus of US$43.1 million. This proposal provides a better price range for young XDEMVY prices from 1,850 US dollars to 1,920 US dollars wider, and this started in August.

Tarsus Pharmaceuticals also had a direct-to-consumer (DTC) marketing campaign for the creation of XDEMVY, which was a specialist in promoting products to a general audience. The Oppenheim analyst did this research and tracked management’s management of strategic initiatives as well as other ideas for the top Outperform rating and pricing of US$63.

Tarsus Pharmaceuticals written quarters services and financial agency are very helpful for increasing XDEMVY investment volumes and business management. Le Beibehaltene Outperform-Rating et le Kursziel von Oppenheimer spiegeln das Vertrauen die Auschten des Unternehmens et seine Fähigkeit broader, die Erwartungen im Wettbewerbsintensiven Pharmamarkt zu erfüllen.

In addition to current results, Tarsus Pharmaceuticals has a positive response to the Markteinführung ihres Produkts Xdemvy. Guggenheim organized an agency for Tarsus-Aktien and supported the development study of Xdemvy, October 4 and 4.104 took place and gave registration for the production brand.

I wrote a budget for the 2024 quarter of $42,600 for the Xdemvy network, with the management prognosis of a 10% reduction in investment by two quarters.

Oppenheimer had positive results for the Tarsus festival and achieved an outperformance rating aufgrund der wachsenden Anerkennung von Demodex-Blepharitis sous Augenärzten, was a response to recommendations for Xdemvy führt.

Tarsus Pharmaceuticals obtained an excellent guarantee of its financial budget for the second quarter of 2024, with an investment of 40 million US dollars, a guarantee of 65% from the company of the previous quarter, which was taken into account by investors . Xdemvy.

Das Unternehmen plant, seine Vertriebsmannschaft zu erweitern et später im Jahr a Direct-to-Consumer-Werbekampagne zu starten. New health insurance will be taken in 2025 and Tarsus will be ready to expand its market segment.

Trotz potenzieller Herausforderungen, einschließlich eines möglichen Rückgangs neuer Verschreibungen im dritten Quartal et leicht erhöhter Brutto-Netto-Rabatte aufgrund de Medicare-Donut-Hole-Problems, bleibt Tarsus optimistic hinsichtlich seiner Wachstumsperspektiven.

InvestingPro Erkenntnisse

Zur Ergänzung des Ausblicks von Oppenheimer auf Tarsus Pharmaceuticals (NASDAQ:TARS) liefern actual Daten von InvestingPro zusätzlichen Kontext für Investoren. The companies’ private equity was worth US$1.39 billion and was in a current position in the pharmaceutical sector. It turns out that Tarsus had a forward rate of 566.99% in the last month of the second quarter of 2024, with the analysts’ focus on researching XDEMVY.

InvestingPro-Tipps was founded by Tarsus plus Bargeld als Schulden in the balance sheet period, with financial flexibility for the marketing initiative like the new DTC campaign for XDEMVY already available. Darüber hinaus erwarten Analysten ein Umsatzwachstum im laufenden Jahr, was Oppenheimer’s very good overall prognosis underestimated.

The strong return of entrepreneurs in the three-month letzten with an overall trend of 34.3% and an accelerated return of 178.03% during the year shows the positive development of Tarsus’ strategy and production on the walk. These Kennzahlen are boosting the outperform rating and optimism from top analysts.

For investors, an analysis of Tarsus Pharmaceuticals’ financial condition and business position, such as that of Tarsus Pharmaceuticals, gives you 10 free tips from InvestingPro, an overview of Australian tips in the wet intensive pharmaceutical region.

This Übersetzung wurde mithilfe künstlicher Intelligenz erstellt. Please note that further information is required to provide additional information.